Literature DB >> 23473950

Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions.

Elisabet E Manasanch1, Sigurdur Y Kristinsson, Ola Landgren.   

Abstract

Epidemiologic studies provide an insight into the etiology of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, which indicates that repetitive immune stimulation and genetic factors play an important role. Here, the current understanding on the causes of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia are reviewed. Recent studies of the literature are discussed, and future population-based studies are proposed to further elucidate the molecular mechanisms that underlie these associations. Finally, the clinical implications of these data are outlined, and perspectives on clinical follow-up and counseling are provided.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23473950      PMCID: PMC7243894          DOI: 10.1016/j.clml.2013.02.002

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  33 in total

1.  Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005.

Authors:  Jeevan Sekhar; Kristen Sanfilippo; Qin Zhang; Kathryn Trinkaus; Ravi Vij; Daniel Morgensztern
Journal:  Leuk Lymphoma       Date:  2012-02-13

2.  Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.

Authors:  Matthew F Rudd; Gabrielle S Sellick; Emily L Webb; Daniel Catovsky; Richard S Houlston
Journal:  Blood       Date:  2006-03-30       Impact factor: 22.113

Review 3.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

4.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

5.  Malignant evolution of asymptomatic monoclonal IgM after seven and fifteen years in two siblings of a patient with Waldenström's macroglobulinemia.

Authors:  J M Fine; P Lambin; M Massari; P Leroux
Journal:  Acta Med Scand       Date:  1982-05

6.  Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

Authors:  Regan H Royer; Jill Koshiol; Therese R Giambarresi; Linda G Vasquez; Ruth M Pfeiffer; Mary L McMaster
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

7.  Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.

Authors:  M Björkholm; E Johansson; D Papamichael; F Celsing; J Matthews; T A Lister; A Z S Rohatiner
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

8.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

Review 9.  Waldenström macroglobulinemia: my way.

Authors:  Morie Gertz
Journal:  Leuk Lymphoma       Date:  2012-08-25

Review 10.  Genetic susceptibility to lymphoma.

Authors:  Christine F Skibola; John D Curry; Alexandra Nieters
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

View more
  4 in total

1.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.

Authors:  Todd M Gibson; Lindsay M Morton; Meredith S Shiels; Christina A Clarke; Eric A Engels
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

2.  Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Authors:  V S Tompkins; R Sompallae; T R Rosean; S Walsh; M Acevedo; A L Kovalchuk; S-S Han; X Jing; C Holman; J E Rehg; S Herms; J S Sunderland; H C Morse; S Janz
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

3.  Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis.

Authors:  Yan-Hua Zheng; Li Xu; Chun Cao; Juan Feng; Hai-Long Tang; Mi-Mi Shu; Guang-Xun Gao; Xie-Qun Chen
Journal:  Onco Targets Ther       Date:  2019-04-11       Impact factor: 4.147

Review 4.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.